Viemed (VMD) Q2 Revenue Rises 15%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 07 2025
0mins
Should l Buy VMD?
Source: Fool
Q2 2025 Financial Performance: Viemed Healthcare reported record quarterly revenue of $63.1 million, slightly below analyst expectations, with GAAP earnings per share at $0.08. Despite these misses, the company saw significant year-over-year growth in patient volumes and raised its full-year revenue and Adjusted EBITDA guidance following the acquisition of Lehan’s Medical Equipment.
Strategic Growth Initiatives: The company is expanding beyond core respiratory therapy into additional home healthcare segments, including sleep therapy and women's health, while managing shifts in service mix that impact gross margins. Ongoing focus on operational efficiency and regulatory compliance will be crucial as they integrate new acquisitions and adapt to changing reimbursement policies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VMD
About VMD
Viemed Healthcare, Inc. is an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, including non-invasive ventilators (NIV), sleep therapy, staffing, and other complementary products and services. The Company focuses on in-home treatment with clinical practitioners providing therapy, education and counseling to patients in their homes using high-touch and high-tech services. The Company’s products and services include Home Medical Equipment, In-home sleep testing, and Healthcare staffing. Home Medical Equipment provides respiratory and other home medical equipment solutions, including home ventilation, bi-level positive airway pressure (BiPAP) and continuous positive airway pressure (CPAP) devices, percussion vests, oxygen concentrators, breast pumps for women, respiratory devices and other medical equipment. It offers in-home sleep apnea testing services. The Company also provides healthcare staffing and recruitment services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Viemed (VMD) Q4 2025 Earnings Call Transcript
See More
Viemed Healthcare Q4 Earnings Beat Expectations
- Earnings Highlights: Viemed Healthcare reported Q4 GAAP EPS of $0.14, beating expectations by $0.05, although revenue of $76.2 million, up 25.5% year-over-year, missed by $1.15 million, indicating challenges in balancing growth and profitability.
- Adjusted EBITDA Growth: For the year ending December 31, 2025, adjusted EBITDA reached $18.2 million, with a record $61.4 million for the full year, demonstrating the company's ability to maintain strong profitability amid ongoing growth, which bolsters investor confidence.
- Significant Free Cash Flow Increase: The free cash flow for 2025 totaled $28.1 million, a substantial increase from $11.6 million in 2024, reflecting improvements in operational efficiency and cash management, which will support future investments and shareholder returns.
- 2026 Financial Guidance: The company expects net revenue for 2026 to be in the range of $310 million to $320 million, below the market consensus of $328.73 million, with adjusted EBITDA projected between $65 million and $69 million, indicating a cautiously optimistic outlook for future growth.
See More
Viemed Healthcare Authorizes Share Repurchase Program
- Repurchase Program Initiation: Viemed Healthcare's board approved a share repurchase program on Wednesday, allowing for the buyback of up to 1,930,131 common shares, which represents approximately 5% of its issued shares as of March 4, 2026.
- Flexible Repurchase Methods: The company plans to execute repurchases through open market or block purchases, adhering to applicable securities laws, including Rule 10b-18 under the Securities Exchange Act of 1934, ensuring compliance and transparency.
- Daily Purchase Limitations: Daily repurchases will be capped at 25% of the average daily trading volume over the preceding four weeks, which aims to mitigate market volatility and protect shareholder interests during the buyback period.
- Share Cancellation Policy: Shares repurchased under this program will be canceled, and while the company has indicated that there is no assurance regarding the number of shares to be repurchased, the ability to discontinue purchases at any time reflects a cautious and flexible approach to capital management.
See More
Viemed Healthcare to Announce Q4 Earnings on March 5
- Earnings Announcement: Viemed Healthcare is set to release its Q4 earnings on March 5 before market open, with consensus EPS estimates at $0.13, reflecting a 30% year-over-year increase.
- Revenue Expectations: The company anticipates Q4 revenue of $77.7 million, representing a 28% year-over-year growth, which underscores its robust performance in the small-cap healthcare sector amid ongoing market demand.
- Investor Confidence: Viemed Healthcare's quant rating indicates strong investor optimism regarding its valuation, particularly in light of buoyant cash flow, which further bolsters market confidence in its future growth prospects.
- Technical Analysis: Small-cap healthcare stocks are surging, with Viemed Healthcare's stock price surpassing the 200-day moving average, indicating strong momentum in the market and potential investment opportunities.
See More
Viemed to Host Year End 2025 Earnings Call on March 5
- Earnings Call Announcement: Viemed Healthcare will host its Year End 2025 earnings conference call on March 5, 2026, at 11:00 a.m. ET, aimed at providing the latest financial performance updates to investors and stakeholders.
- Participation Details: Interested parties can join the call by dialing 877-407-6176 (US Toll-Free) or +1 201-689-8451 (International), ensuring global investors have convenient access to the company's updates.
- Webcast Replay Availability: Following the live call, a replay will be accessible in the Investor Relations section of the company's website, enhancing information transparency and investor engagement.
- Company Overview: Viemed Healthcare focuses on home medical equipment and post-acute healthcare services in the U.S., emphasizing efficient chronic disease management through high-quality home care and technology-enabled support, showcasing its strategic positioning in the healthcare sector.
See More
Small-Cap Stocks Surge, Led by Healthcare Sector
- Small-Cap Outperformance: Year-to-date in 2026, the iShares Core S&P Small-Cap ETF (IJR) has surged 10.9%, significantly outperforming the SPDR S&P 500 ETF Trust (SPY) which only rose 1.4%, indicating a potential shift in investor sentiment towards small-cap stocks after years of underperformance.
- Healthcare Stocks Leading: Viemed Healthcare (VMD) tops the list with a last price percentage of 19.89% versus the 200-day simple moving average (200DSMA), showcasing its strong market performance and likely attracting investor interest and capital inflow.
- Strong Performers in Healthcare: Following VMD, MannKind (MNKD) and Verano Holdings (VRNO) exhibit impressive figures of 18.85% and 17.30% respectively against the 200DSMA, highlighting their competitive positioning and growth potential in the healthcare sector.
- Healthcare Sector Dynamics: Notably, 22 out of 23 healthcare firms reported earnings per share (EPS) beats this week, reflecting robust performance in the healthcare industry, which may bolster investor confidence and drive further gains in healthcare stocks.
See More
Viemed (VMD) Q4 2025 Earnings Call Transcript
See More
Viemed Healthcare Q4 Earnings Beat Expectations
- Earnings Highlights: Viemed Healthcare reported Q4 GAAP EPS of $0.14, beating expectations by $0.05, although revenue of $76.2 million, up 25.5% year-over-year, missed by $1.15 million, indicating challenges in balancing growth and profitability.
- Adjusted EBITDA Growth: For the year ending December 31, 2025, adjusted EBITDA reached $18.2 million, with a record $61.4 million for the full year, demonstrating the company's ability to maintain strong profitability amid ongoing growth, which bolsters investor confidence.
- Significant Free Cash Flow Increase: The free cash flow for 2025 totaled $28.1 million, a substantial increase from $11.6 million in 2024, reflecting improvements in operational efficiency and cash management, which will support future investments and shareholder returns.
- 2026 Financial Guidance: The company expects net revenue for 2026 to be in the range of $310 million to $320 million, below the market consensus of $328.73 million, with adjusted EBITDA projected between $65 million and $69 million, indicating a cautiously optimistic outlook for future growth.
See More
Viemed Healthcare Authorizes Share Repurchase Program
- Repurchase Program Initiation: Viemed Healthcare's board approved a share repurchase program on Wednesday, allowing for the buyback of up to 1,930,131 common shares, which represents approximately 5% of its issued shares as of March 4, 2026.
- Flexible Repurchase Methods: The company plans to execute repurchases through open market or block purchases, adhering to applicable securities laws, including Rule 10b-18 under the Securities Exchange Act of 1934, ensuring compliance and transparency.
- Daily Purchase Limitations: Daily repurchases will be capped at 25% of the average daily trading volume over the preceding four weeks, which aims to mitigate market volatility and protect shareholder interests during the buyback period.
- Share Cancellation Policy: Shares repurchased under this program will be canceled, and while the company has indicated that there is no assurance regarding the number of shares to be repurchased, the ability to discontinue purchases at any time reflects a cautious and flexible approach to capital management.
See More
Viemed Healthcare to Announce Q4 Earnings on March 5
- Earnings Announcement: Viemed Healthcare is set to release its Q4 earnings on March 5 before market open, with consensus EPS estimates at $0.13, reflecting a 30% year-over-year increase.
- Revenue Expectations: The company anticipates Q4 revenue of $77.7 million, representing a 28% year-over-year growth, which underscores its robust performance in the small-cap healthcare sector amid ongoing market demand.
- Investor Confidence: Viemed Healthcare's quant rating indicates strong investor optimism regarding its valuation, particularly in light of buoyant cash flow, which further bolsters market confidence in its future growth prospects.
- Technical Analysis: Small-cap healthcare stocks are surging, with Viemed Healthcare's stock price surpassing the 200-day moving average, indicating strong momentum in the market and potential investment opportunities.
See More
Viemed to Host Year End 2025 Earnings Call on March 5
- Earnings Call Announcement: Viemed Healthcare will host its Year End 2025 earnings conference call on March 5, 2026, at 11:00 a.m. ET, aimed at providing the latest financial performance updates to investors and stakeholders.
- Participation Details: Interested parties can join the call by dialing 877-407-6176 (US Toll-Free) or +1 201-689-8451 (International), ensuring global investors have convenient access to the company's updates.
- Webcast Replay Availability: Following the live call, a replay will be accessible in the Investor Relations section of the company's website, enhancing information transparency and investor engagement.
- Company Overview: Viemed Healthcare focuses on home medical equipment and post-acute healthcare services in the U.S., emphasizing efficient chronic disease management through high-quality home care and technology-enabled support, showcasing its strategic positioning in the healthcare sector.
See More
Small-Cap Stocks Surge, Led by Healthcare Sector
- Small-Cap Outperformance: Year-to-date in 2026, the iShares Core S&P Small-Cap ETF (IJR) has surged 10.9%, significantly outperforming the SPDR S&P 500 ETF Trust (SPY) which only rose 1.4%, indicating a potential shift in investor sentiment towards small-cap stocks after years of underperformance.
- Healthcare Stocks Leading: Viemed Healthcare (VMD) tops the list with a last price percentage of 19.89% versus the 200-day simple moving average (200DSMA), showcasing its strong market performance and likely attracting investor interest and capital inflow.
- Strong Performers in Healthcare: Following VMD, MannKind (MNKD) and Verano Holdings (VRNO) exhibit impressive figures of 18.85% and 17.30% respectively against the 200DSMA, highlighting their competitive positioning and growth potential in the healthcare sector.
- Healthcare Sector Dynamics: Notably, 22 out of 23 healthcare firms reported earnings per share (EPS) beats this week, reflecting robust performance in the healthcare industry, which may bolster investor confidence and drive further gains in healthcare stocks.
See More
